

Systemic Anti Cancer Treatment Protocol

**Docetaxel
Gastric**

**PROTOCOL REF: MPHAUGIDOC
(Version No: 1.0)**

Approved for use in:

Second line treatment of locally advanced and metastatic gastric / gastro-oesophageal junction adenocarcinoma

PS 0-1

Dosage:

Drug	Dosage	Route	Frequency
Dexamethasone	8mg BD	PO	Three days starting 24 hours before docetaxel
Docetaxel	75mg/m ²	IV	Every 21 days

Supportive treatments:

Domperidone 10mg oral tablets, up to 3 times a day or as required

Extravasation risk:

Vesicant – refer to trust / network extravasation policy – specific treatment may apply

Administration:

Day	Drug	Dosage	Route	Diluent and Rate
1	Dexamethasone	8mg BD	PO	For 3 days starting 24 hours before docetaxel
1	Docetaxel	75mg/m ²	IV	Sodium chloride 0.9% 250mL over 60 minutes

Repeat every 21 days for 6 cycles

Issue Date: 14 th July 2017	Page 1 of 3	Protocol reference: MPHAUGIDOC
Author: Jenny Wood	Authorised by: Dr. R Sripadam	Version No: 1.0

Notes:

Be aware of hypersensitivity and infusion related reactions – see below

Ensure oral pre-med dexamethasone has been taken before giving docetaxel

If dexamethasone pre-meds have **not** been taken then additional **dexamethasone IV 8mg** may be administered prior to starting the docetaxel infusion

Main Toxicities:

Myelosuppression, hypersensitivity and infusion related, cutaneous reactions and nail changes, fluid retention, alopecia, peripheral neurotoxicity, stomatitis, diarrhoea, ovarian failure/infertility

Investigations and treatment plan

	Pre	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5	Cycle 6	Comments
Medical Assessment	X		X		X		X	Alternate cycles
Nursing Assessment	X	X	X	X	X	X	X	Every cycle
FBC	X	X	X	X	X	X	X	Every cycle
U&E & LFT	X	X	X	X	X	X	X	Every cycle
CT scan	X			X				As clinically indicated
Informed Consent	X							
Blood pressure measurement	X							Repeat if clinically indicated
PS recorded	X	X	X	X	X	X	X	Every cycle
Toxicities documented	X	X	X	X	X	X	X	Every cycle
Weight recorded	X	X	X	X	X	X	X	Every cycle

Dose Modifications and Toxicity Management:

Haematological toxicity

Proceed on day 1 if:-

ANC $\geq 1.5 \times 10^9/L$	Platelets $\geq 100 \times 10^9/L$
------------------------------	------------------------------------

Delay 1 week on day 1 if:-

ANC $\leq 1.4 \times 10^9/L$	Platelets $\leq 99 \times 10^9/L$
------------------------------	-----------------------------------

If greater than 7 days required for FBC recovery then dose reduce to 60mg/m²

Non-haematological toxicity

Renal	No dose adjustments needed
Hepatic	If bilirubin > 22mmol/l or ALT/AST > 3.5 x ULN and ALP > 6 x ULN not recommended – delay treatment and refer to consultant
Cutaneous	Grade 1 persistent or Grade 2 – delay treatment until resolved to grade 0-1. Restart at same dose Grade 3 restart once recovered at 60mg/m ²
Neuropathy	Grade 2 – delay treatment until resolved to grade 1. Reduce dose to 60mg/m ² Grade 3 or 4 – stop docetaxel permanently
Other grade 3/4 reactions	Discontinue treatment

References:

Cougar-O2 trial; Lancet Oncology 2014 15(1) 78-86

Issue Date: 14 th July 2017	Page 3 of 3	Protocol reference: MPHAUGIDOC
Author: Jenny Wood	Authorised by: Dr. R Sripadam	Version No: 1.0